Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Abstract Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on veneto...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sasanka Handunnetti, Mary Ann Anderson, Andrew W. Roberts, Matthew S. Davids, Shuo Ma, Michelle Boyer, Jennifer Arzt, Abdullah Al Masud, Relja Popovic, Amanda Jacobson, Su Y. Kim, John F. Seymour
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2021-05-01
Series:	eJHaem
Assuntos:	chronic lymphocytic leukemia relapsed/refractory rituximab small lymphocytic lymphoma venetoclax
Acceso en liña:	https://doi.org/10.1002/jha2.177
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!